Myriad Genetics Inc (MYGN) - Medical Equipment - Deals and Alliances Profile
- GDME7218D
- Pages: 68
- October 2018
- Total Views:1213
- Region : North America
- GlobalData
- Equity Research Report
Details
Summary
Myriad Genetics Inc (Myriad) is a specialty molecular diagnostic company, which discovers and commercializes molecular diagnostic tests, personalized medicine and services for major diseases. The company's product portfolio includes molecular diagnostic testing products that analyze genes, their expression levels and corresponding proteins to assess a person risk for developing disease later in life, accurately diagnose disease and determine a patient's likelihood of responding to a particular drug. It also provides an array of pharmaceutical and clinical services. Myriad markets its products through its sales force in Europe and Canada and through distributor agreements in Latin American, Middle Eastern, Asian and African countries. The company has operations in the US, Spain, France, Switzerland, the UK, Canada, the Netherlands and Italy. Myriad is headquartered in Salt Lake City, Utah, the US.
Myriad Genetics Inc (MYGN)-Medical Equipment-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table Of Content
Scope
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Myriad Genetics Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 6
Myriad Genetics Inc, Medical Equipment Deals By Type, 2012 to YTD 2018 7
Myriad Genetics Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 8
Myriad Genetics Inc, Medical Equipment, Deals By Market, 2012 to YTD 2018 9
Myriad Genetics Inc, Medical Equipment, Deals Summary, 2012 to YTD 2018 10
Myriad Genetics Inc, Medical Equipment, Deal Details 13
Venture Financing 13
Myriad Genetics to Raise Funds through Venture Financing 13
AssureRx Health Raises Additional USD15 Million in Series D Financing 14
AssureRx Health Raises USD7 Million in Venture Financing 15
Counsyl Raises USD 28 Million In Series D Financing 17
RainDance Technologies Raises USD 20 Million In Series E Financing 18
Crescendo Bioscience Raises USD 28 Million In Series D Financing 20
Counsyl Secures USD7.5 Million in Series C Funding 22
Assurex Health Secures USD12.5 Million in Series C Funding Round 23
Counsyl Secures USD34 Million in Series B Round of Funding 24
Assurex Health Secures USD8 Million in Venture Funding Round 25
Private Equity 26
Perceptive Advisors Invests USD80 Million in Counsyl 26
Partnerships 27
Myriad Genetics Enters into Licensing Agreement with Institut Curie and INSERM 27
Myriad Genetics Enters into Licensing Agreement With Children's Medical Center 28
Myriad Genetics Enters into Licensing Agreement with University of Texas 29
Myriad Genetics Enters Into Licensing Agreement For RAD51C Gene 30
Myriad Genetics and Pfizer Enter into Agreement 31
Sividon Diagnostics Enters into Co-Marketing Agreement with Virchow Labs and Ready Ruixin 32
Myriad Genetics Expands Agreement with AstraZeneca 33
Myriad Genetics Enters Into Co-Marketing Agreement With Sividon Diagnostics For EndoPredict Test 34
Myriad Enters Into Research Agreement With Janssen Research & Development 35
Myriad Genetics Expands Agreement with AstraZeneca for Olaparib 36
DaVita Enters Into Agreement With Myriad Genetics For Protein Biomarker Discovery 37
Mount Sinai Genetic Testing Lab And Counsyl Partner To Expand Screening For Genetic Diseases 38
Bio-Rad Labs Enters Into Distribution Agreement With Myriad RBM For Multiplex Biomarker Kits 39
Acquisition 40
Myriad Genetics Acquires Counsyl for USD375 Million 40
Myriad Genetics Acquires Assurex Health for USD351.6 Million 42
Myriad Genetics Acquires Sividon Diagnostics 44
Myriad Genetics Completes Acquisition Of Crescendo Bioscience For USD 270 Million 45
Myriad Genetics Inc-Key Competitors 47
Myriad Genetics Inc-Key Employees 48
Myriad Genetics Inc-Locations And Subsidiaries 49
Head Office 49
Other Locations & Subsidiaries 49
Recent Developments 51
Financial Announcements 51
Aug 21, 2018: Myriad Genetics reports fiscal fourth-quarter and full-year 2018 financial results 51
May 08, 2018: Myriad Genetics Reports Fiscal Third-Quarter 2018 Financial Results 54
Feb 06, 2018: Myriad Genetics Reports Fiscal Second-Quarter 2018 Financial Results 56
Nov 07, 2017: Myriad Genetics Reports Fiscal First-Quarter 2018 Financial Results 58
May 02, 2017: Myriad Genetics Reports Fiscal Third-Quarter 2017 Financial Results 59
Feb 07, 2017: Myriad Genetics Reports Fiscal Second-Quarter 2017 Financial Results 61
Legal and Regulatory 63
Apr 23, 2018: Federman & Sherwood Announces Filing of Securities Class Action Lawsuit Against Myriad Genetics, Inc. 63
Government and Public Interest 64
Sep 25, 2018: Myriad Announces Publication of Variant Reclassification Study in the Journal of the American Medical Association 64
Product News 65
Apr 17, 2017: Study Finds Wide Gap in Quality of BRCA1/2 Variant Classification Between Myriad Genetics and A Common Public Database 65
Other Significant Developments 67
Oct 02, 2017: Myriad Genetics Highlights Strong Commitment to Preventing and Fighting Breast Cancer as Part of Breast Cancer Awareness Month 67
Appendix 68
Methodology 68
About GlobalData 68
Contact Us 68
Disclaimer 68
List Of Figure
List of Figures
Myriad Genetics Inc, Medical Equipment, Deals by Type, 2012 to YTD 2018 2
Myriad Genetics Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 2
Myriad Genetics Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 2
Myriad Genetics Inc, Medical Equipment, Deals By Market, 2012 to YTD 2018 2
Myriad Genetics Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 6
Myriad Genetics Inc, Medical Equipment, Deals by Type, 2012 to YTD 2018 7
Myriad Genetics Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 8
Myriad Genetics Inc, Medical Equipment, Deals by Market, 2012 to YTD 2018 9
List Of Table
List of Tables
Myriad Genetics Inc, Medical Equipment, Key Facts, 2018 2
Myriad Genetics Inc, Medical Equipment, Deals Summary, 2012 to YTD 2018 2
Myriad Genetics Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 6
Myriad Genetics Inc, Medical Equipment Deals By Type, 2012 to YTD 2018 7
Myriad Genetics Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 8
Myriad Genetics Inc, Deals By Market, 2012 to YTD 2018 9
Myriad Genetics Inc, Medical Equipment, Deals Summary, 2012 to YTD 2018 10
Myriad Genetics to Raise Funds through Venture Financing 13
AssureRx Health Raises Additional USD15 Million in Series D Financing 14
AssureRx Health Raises USD7 Million in Venture Financing 15
Counsyl Raises USD 28 Million In Series D Financing 17
RainDance Technologies Raises USD 20 Million In Series E Financing 18
Crescendo Bioscience Raises USD 28 Million In Series D Financing 20
Counsyl Secures USD7.5 Million in Series C Funding 22
Assurex Health Secures USD12.5 Million in Series C Funding Round 23
Counsyl Secures USD34 Million in Series B Round of Funding 24
Assurex Health Secures USD8 Million in Venture Funding Round 25
Perceptive Advisors Invests USD80 Million in Counsyl 26
Myriad Genetics Enters into Licensing Agreement with Institut Curie and INSERM 27
Myriad Genetics Enters into Licensing Agreement With Children's Medical Center 28
Myriad Genetics Enters into Licensing Agreement with University of Texas 29
Myriad Genetics Enters Into Licensing Agreement For RAD51C Gene 30
Myriad Genetics and Pfizer Enter into Agreement 31
Sividon Diagnostics Enters into Co-Marketing Agreement with Virchow Labs and Ready Ruixin 32
Myriad Genetics Expands Agreement with AstraZeneca 33
Myriad Genetics Enters Into Co-Marketing Agreement With Sividon Diagnostics For EndoPredict Test 34
Myriad Enters Into Research Agreement With Janssen Research & Development 35
Myriad Genetics Expands Agreement with AstraZeneca for Olaparib 36
DaVita Enters Into Agreement With Myriad Genetics For Protein Biomarker Discovery 37
Mount Sinai Genetic Testing Lab And Counsyl Partner To Expand Screening For Genetic Diseases 38
Bio-Rad Labs Enters Into Distribution Agreement With Myriad RBM For Multiplex Biomarker Kits 39
Myriad Genetics Acquires Counsyl for USD375 Million 40
Myriad Genetics Acquires Assurex Health for USD351.6 Million 42
Myriad Genetics Acquires Sividon Diagnostics 44
Myriad Genetics Completes Acquisition Of Crescendo Bioscience For USD 270 Million 45
Myriad Genetics Inc, Key Competitors 47
Myriad Genetics Inc, Key Employees 48
Myriad Genetics Inc, Subsidiaries 49
Licence Rights
Single User License:
Report can be used by individual purchaser only
Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office
Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company
Section Purchase
INQUIRE FOR COVID-19 IMPACT ANALYSIS
Products and Companies
Products
Myriad Genetics Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Company Profile
Company Profile Title
Summary
Myriad Genetics Inc (Myriad) is a specialty molecular diagnostic company, which discovers and commercializes molecular diagnostic tests, personalized medicine and services for major diseases. The company's product portfolio includes molecular diagnostic testing products that analyze genes, their expression levels and corresponding proteins to assess a person risk for developing disease later in life, accurately diagnose disease and determine a patient's likelihood of responding to a particular drug. It also provides an array of pharmaceutical and clinical services. Myriad markets its products through its sales force in Europe and Canada and through distributor agreements in Latin American, Middle Eastern, Asian and African countries. The company has operations in the US, Spain, France, Switzerland, the UK, Canada, the Netherlands and Italy. Myriad is headquartered in Salt Lake City, Utah, the US.
Myriad Genetics Inc (MYGN)-Medical Equipment-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Scope
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Myriad Genetics Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 6
Myriad Genetics Inc, Medical Equipment Deals By Type, 2012 to YTD 2018 7
Myriad Genetics Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 8
Myriad Genetics Inc, Medical Equipment, Deals By Market, 2012 to YTD 2018 9
Myriad Genetics Inc, Medical Equipment, Deals Summary, 2012 to YTD 2018 10
Myriad Genetics Inc, Medical Equipment, Deal Details 13
Venture Financing 13
Myriad Genetics to Raise Funds through Venture Financing 13
AssureRx Health Raises Additional USD15 Million in Series D Financing 14
AssureRx Health Raises USD7 Million in Venture Financing 15
Counsyl Raises USD 28 Million In Series D Financing 17
RainDance Technologies Raises USD 20 Million In Series E Financing 18
Crescendo Bioscience Raises USD 28 Million In Series D Financing 20
Counsyl Secures USD7.5 Million in Series C Funding 22
Assurex Health Secures USD12.5 Million in Series C Funding Round 23
Counsyl Secures USD34 Million in Series B Round of Funding 24
Assurex Health Secures USD8 Million in Venture Funding Round 25
Private Equity 26
Perceptive Advisors Invests USD80 Million in Counsyl 26
Partnerships 27
Myriad Genetics Enters into Licensing Agreement with Institut Curie and INSERM 27
Myriad Genetics Enters into Licensing Agreement With Children's Medical Center 28
Myriad Genetics Enters into Licensing Agreement with University of Texas 29
Myriad Genetics Enters Into Licensing Agreement For RAD51C Gene 30
Myriad Genetics and Pfizer Enter into Agreement 31
Sividon Diagnostics Enters into Co-Marketing Agreement with Virchow Labs and Ready Ruixin 32
Myriad Genetics Expands Agreement with AstraZeneca 33
Myriad Genetics Enters Into Co-Marketing Agreement With Sividon Diagnostics For EndoPredict Test 34
Myriad Enters Into Research Agreement With Janssen Research & Development 35
Myriad Genetics Expands Agreement with AstraZeneca for Olaparib 36
DaVita Enters Into Agreement With Myriad Genetics For Protein Biomarker Discovery 37
Mount Sinai Genetic Testing Lab And Counsyl Partner To Expand Screening For Genetic Diseases 38
Bio-Rad Labs Enters Into Distribution Agreement With Myriad RBM For Multiplex Biomarker Kits 39
Acquisition 40
Myriad Genetics Acquires Counsyl for USD375 Million 40
Myriad Genetics Acquires Assurex Health for USD351.6 Million 42
Myriad Genetics Acquires Sividon Diagnostics 44
Myriad Genetics Completes Acquisition Of Crescendo Bioscience For USD 270 Million 45
Myriad Genetics Inc-Key Competitors 47
Myriad Genetics Inc-Key Employees 48
Myriad Genetics Inc-Locations And Subsidiaries 49
Head Office 49
Other Locations & Subsidiaries 49
Recent Developments 51
Financial Announcements 51
Aug 21, 2018: Myriad Genetics reports fiscal fourth-quarter and full-year 2018 financial results 51
May 08, 2018: Myriad Genetics Reports Fiscal Third-Quarter 2018 Financial Results 54
Feb 06, 2018: Myriad Genetics Reports Fiscal Second-Quarter 2018 Financial Results 56
Nov 07, 2017: Myriad Genetics Reports Fiscal First-Quarter 2018 Financial Results 58
May 02, 2017: Myriad Genetics Reports Fiscal Third-Quarter 2017 Financial Results 59
Feb 07, 2017: Myriad Genetics Reports Fiscal Second-Quarter 2017 Financial Results 61
Legal and Regulatory 63
Apr 23, 2018: Federman & Sherwood Announces Filing of Securities Class Action Lawsuit Against Myriad Genetics, Inc. 63
Government and Public Interest 64
Sep 25, 2018: Myriad Announces Publication of Variant Reclassification Study in the Journal of the American Medical Association 64
Product News 65
Apr 17, 2017: Study Finds Wide Gap in Quality of BRCA1/2 Variant Classification Between Myriad Genetics and A Common Public Database 65
Other Significant Developments 67
Oct 02, 2017: Myriad Genetics Highlights Strong Commitment to Preventing and Fighting Breast Cancer as Part of Breast Cancer Awareness Month 67
Appendix 68
Methodology 68
About GlobalData 68
Contact Us 68
Disclaimer 68
List Of Figure
List of Figures
Myriad Genetics Inc, Medical Equipment, Deals by Type, 2012 to YTD 2018 2
Myriad Genetics Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 2
Myriad Genetics Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 2
Myriad Genetics Inc, Medical Equipment, Deals By Market, 2012 to YTD 2018 2
Myriad Genetics Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 6
Myriad Genetics Inc, Medical Equipment, Deals by Type, 2012 to YTD 2018 7
Myriad Genetics Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 8
Myriad Genetics Inc, Medical Equipment, Deals by Market, 2012 to YTD 2018 9
List Of Table
List of Tables
Myriad Genetics Inc, Medical Equipment, Key Facts, 2018 2
Myriad Genetics Inc, Medical Equipment, Deals Summary, 2012 to YTD 2018 2
Myriad Genetics Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 6
Myriad Genetics Inc, Medical Equipment Deals By Type, 2012 to YTD 2018 7
Myriad Genetics Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 8
Myriad Genetics Inc, Deals By Market, 2012 to YTD 2018 9
Myriad Genetics Inc, Medical Equipment, Deals Summary, 2012 to YTD 2018 10
Myriad Genetics to Raise Funds through Venture Financing 13
AssureRx Health Raises Additional USD15 Million in Series D Financing 14
AssureRx Health Raises USD7 Million in Venture Financing 15
Counsyl Raises USD 28 Million In Series D Financing 17
RainDance Technologies Raises USD 20 Million In Series E Financing 18
Crescendo Bioscience Raises USD 28 Million In Series D Financing 20
Counsyl Secures USD7.5 Million in Series C Funding 22
Assurex Health Secures USD12.5 Million in Series C Funding Round 23
Counsyl Secures USD34 Million in Series B Round of Funding 24
Assurex Health Secures USD8 Million in Venture Funding Round 25
Perceptive Advisors Invests USD80 Million in Counsyl 26
Myriad Genetics Enters into Licensing Agreement with Institut Curie and INSERM 27
Myriad Genetics Enters into Licensing Agreement With Children's Medical Center 28
Myriad Genetics Enters into Licensing Agreement with University of Texas 29
Myriad Genetics Enters Into Licensing Agreement For RAD51C Gene 30
Myriad Genetics and Pfizer Enter into Agreement 31
Sividon Diagnostics Enters into Co-Marketing Agreement with Virchow Labs and Ready Ruixin 32
Myriad Genetics Expands Agreement with AstraZeneca 33
Myriad Genetics Enters Into Co-Marketing Agreement With Sividon Diagnostics For EndoPredict Test 34
Myriad Enters Into Research Agreement With Janssen Research & Development 35
Myriad Genetics Expands Agreement with AstraZeneca for Olaparib 36
DaVita Enters Into Agreement With Myriad Genetics For Protein Biomarker Discovery 37
Mount Sinai Genetic Testing Lab And Counsyl Partner To Expand Screening For Genetic Diseases 38
Bio-Rad Labs Enters Into Distribution Agreement With Myriad RBM For Multiplex Biomarker Kits 39
Myriad Genetics Acquires Counsyl for USD375 Million 40
Myriad Genetics Acquires Assurex Health for USD351.6 Million 42
Myriad Genetics Acquires Sividon Diagnostics 44
Myriad Genetics Completes Acquisition Of Crescendo Bioscience For USD 270 Million 45
Myriad Genetics Inc, Key Competitors 47
Myriad Genetics Inc, Key Employees 48
Myriad Genetics Inc, Subsidiaries 49
Single User License:
Report can be used by individual purchaser only
Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office
Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company
INQUIRE FOR COVID-19 IMPACT ANALYSIS
Products
Myriad Genetics Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Ask A Question
Our Team Will Assist You in What You Are Looking For
or 
: +91 98100 26150
: ankurgupta1984
Related Reports
Page 179 | 
February 2020
Page 116 | January 2020
Page 235 | January 2020
Page 183 | September 2019
Page 244 | August 2019